1-3 of 3
Lianna J. Marks
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era

Lianna J. Marks, Victor Ritter, Jennifer E. Agrusa, Kala Y. Kamdar, Julie Rivers, Rebecca Gardner, Matthew J. Ehrhardt, Kaitlin J. Devine, Charles A. Phillips, Anne Reilly, Keith August, Joanna Weinstein, Prakash Satwani, Christopher J. Forlenza, Christine Moore Smith, Chelsee Greer, Zeinab Afify, Carol H. Lin, Jennifer A. Belsky, Hilda Ding, David Hoogstra, Keri Toner, Michael P. Link, Liora M. Schultz, Eric J. Lowe, Catherine Aftandilian
Journal: Blood Advances
Blood Adv (2025) 9 (6): 1356–1365.
https://doi.org/10.1182/bloodadvances.2024014745
Published: 2025
Includes: Supplemental data
Journal Articles

Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90

Clinical Trials & Observations
Angela M. Feraco, Yiwang Zhou, Ying Zheng, Lianna J. Marks, Alison Friedmann, Howard J. Weinstein, Michael P. Link, Jamie E. Flerlage
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6665–6667.
https://doi.org/10.1182/bloodadvances.2023010944
Published: 2023
Journal Articles

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J. Deyell, Jamie E. Flerlage, Anna K. Franklin, Jennifer Krajewski, Kasey J. Leger, Lianna J. Marks, Robin E. Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul D. Harker-Murray, Lisa Giulino-Roth
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3225–3231.
https://doi.org/10.1182/bloodadvances.2022009323
Published: 2023
Includes: Supplemental data